Conversely, as the FH enzyme is a homotetramer, it is possible that some point mutants may exhibit dominant negative activity and substantially reduce FH activity in nontumor cells in patients with HLRCC. The gene discussed is FH; the disease is hereditary leiomyomatosis and renal cell cancer.